Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: Survival advantage in comparison to matched historical controls

Blood

Volumn 120, Issue 6, 2012, Pages 1202-1209

  Verstovsek, Srdan ^a   Kantarjian, Hagop M ^a   Estrov, Zeev ^a   Cortes, Jorge E ^a   Thomas, Deborah A ^a   Kadia, Tapan ^a   Pierce, Sherry ^a   Jabbour, Elias ^a   Borthakur, Gautham ^a   Rumi, Elisa ^b   Pungolino, Ester ^c   Morra, Enrica ^c   Caramazza, Domenica ^d   Cazzola, Mario ^b   Passamonti, Francesco ^d  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF PAVIA   (Italy)

^c OSPEDALE NIGUARDA CA GRANDA   (Italy)

^d OSPEDALE DI CIRCOLO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

RUXOLITINIB;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HIGH RISK POPULATION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MYELOFIBROSIS; OPEN STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; SPLENOMEGALY; SURVIVAL; TREATMENT OUTCOME;

EID: 84865192181     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-02-414631     Document Type: Article

References (25)

1. Mesa RA, Niblack J, Wadleigh M, et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international internet-based survey of 1179 MPD patients. Cancer. 2007;109(1):68-76. (Pubitemid 46120195)
2. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113(13):2895-2901.
3. Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115(9):1703-1708.
4. Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011;29(4):392-397.
5. Jakafi (ruxolitinib) full prescribing information. Wilmington, DE: Incyte Corporation; 2011.
6. Quintas-Cardama A, Verstovsek S. Spleen deflation and beyond: the pros and cons of Janus kinase 2 inhibitor therapy for patients with myeloproliferative neoplasms. Cancer 2012 15;118(4):870-877.
7. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366(3):787-798.
8. Mesa R, Verstovsek S, Cervantes F, et al. Comparison of the efficacy of placebo and best available therapy for the treatment of myelofibrosis in the COMFORT studies [abstract]. Blood (ASH Annual Meeting Abstracts). 2011;118(Suppl);Abstract 1753.
9. Mesa RA. How I treat symptomatic splenomegaly in patients with myelofibrosis. Blood. 2009;113(22):5394-5400.
10. Tefferi A, Mesa RA, Nagorney DM, Schroeder G, Silverstein MN. Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood. 2000;95(7):2226-2233. (Pubitemid 30167718)
11. Barbui T, Barosi G, Birgegard G, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011;29(6):761-770.
12. Ballen KK, Shrestha S, Sobocinski KA, et al. Outcome of transplantation for myelofibrosis. Biol Blood Marrow Transplant. 2010;16(3):358-367.
13. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365(9464):1054-1061. (Pubitemid 40386783)
14. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-1790. (Pubitemid 40570926)
15. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7(4):387-397. (Pubitemid 40544655)
16. Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010;363(12):1117-1127.
17. Verstovsek S, Mesa RA, Gotlib JR, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(3):799-807.
18. Tefferi A, Litzow MR, Pardanani A. Long-term outcome of treatment with ruxolitinib in myelofibrosis. N Engl J Med. 2011;365(15):1455-1457.
19. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008;22(1):14-22.
20. Dupriez B, Morel P, Demory JL, et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood. 1996;88(3):1013-1018. (Pubitemid 26333326)
21. Tefferi A, Barosi G, Mesa RA, et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood. 2006;108(5):1497-1503. (Pubitemid 44316114)
22. Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996;17(4):343-346. (Pubitemid 26342716)
23. Cervantes F, Dupriez B, Passamonti F, et al. Improving survival trends in primary myelofibrosis: an international study [prepublished online ahead of print July 23, 2012]. J Clin Oncol. doi:10.1200/JCO.2012.42.0240.
24. Mesa RA, Kantarjian H, Tefferi A, et al. Evaluating the serial use of the myelofibrosis symptom assessment form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer. 2011;117(21):4869-4877.
25. Verstovsek S. Myeloproliferative disorders: JAK2 and beyond. In: American Society of Clinical Oncology 2011 Educational Book. Alexandria, VA: The American Society of Clinical Oncology; 2011:256-261.